ANDA 70445, held by Novitium Pharma. Flurazepam Hydrochloride.
As of Nov 21, 2026, ANDA 70445 (Flurazepam Hydrochloride), held by Novitium Pharma, was first approved by FDA on Mar 20, 1986, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 1986 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Flurazepam Hydrochloride30MG · capsule;oral | Flurazepam Hydrochloride | Discontinued |
| Jan 17, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Feb 8, 2021 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 17, 2017 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 15, 1995 | Supplement 8Manufacturing | Approved | None posted |
| Jul 21, 1993 | Supplement 11Labeling | Approved | None posted |
| Aug 9, 1989 | Supplement 10Labeling | Approved | None posted |
| Jul 20, 1989 | Supplement 9Bioequivalence | Approved | None posted |
| Feb 2, 1988 | Supplement 7Manufacturing | Approved | None posted |
| May 5, 1986 | Supplement 1Manufacturing | Approved | None posted |
| Mar 20, 1986 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters